IMD is a serious bacterial infection caused by the N. meningitidis bacteria, which can lead to dangerous and sometimes fatal diseases including meningitis (inflammation of the lining of the brain and spinal cord), and sepsis (blood poisoning). Learn more about IMD here.
Symptoms of IMD could include sudden fever, drowsiness, irritability or agitation, intense headache, nausea and vomiting, stiff neck, and/or light sensitivity.
IMD could have serious consequences including death, coma, or long-term health problems (in up to 1 in 3 survivors) such as: hearing loss, neurologic disabilities, digit or limb amputations.
A serious infection that can be spread through common adolescent and young-adult behaviours such as close, direct contact, kissing, sharing cups, drinks, and utensils, and close-quartered living.
MenB, caused by N. meningitidis serogroup B bacteria, was associated with 55% of cases of invasive meningococcal disease (IMD) in Canadian adolescents and young adults between 2012 and 2019.
It is the most common cause of invasive meningococcal disease (IMD) in adolescents and young adults in Canada. Learn more about MenB here.
No.
You can assess your risk for MenB by completing this questionnaire.
TRUMENBA is a vaccine to help prevent MenB (Invasive meningococcal disease [IMD] caused by N. meningitidis serogroup B bacteria), for use in individuals aged 10 through 25 years.
National Advisory Committee on Immunization (NACI) recommends that TRUMENBA may be considered as an option for individuals 10–25 years of age who are not at higher risk of meningococcal disease than the general population to reduce the risk of invasive serogroup B meningococcal disease.
Learn more about TRUMENBA here.
TRUMENBA should not be used if you or your child are allergic to the active substance or any other ingredient in the vaccine.
The usual dose is 2 injections given 6 months apart.
If you or your child are at an increased risk of invasive meningococcal disease (IMD) you will be given 3 doses of the vaccine. The second dose will be given 1 month after your initial dose. The third dose will be given at least 4 months after the second dose.
Following either dosing regimen, a booster dose may be considered for those at continued risk of invasive meningococcal disease (IMD). Talk to your doctor to learn more about you or your child's risk of MenB exposure and susceptibility to the disease.
If you forget to go back for your/your child’s second dose, ask your doctor for advice.
TRUMENBA can be given at the same time, albeit in different syringes and at separate injection sites, with the following vaccines: quadrivalent human papillomavirus vaccine (HPV4), meningococcal serogroups A, C, W, Y conjugate vaccine (MenACWY) and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap).
Like all vaccines, TRUMENBA can cause side effects, although not everybody gets them. The most common side effects (reported in more than 1 in 10 people) after having TRUMENBA include headache, nausea, diarrhea, muscle pain, joint pain, redness, swelling and pain at the injection site, chills and fatigue (tiredness). Other common side effects (in more than 1 in 100 people) after having TRUMENBA are vomiting and fever ≥38°C.
Ask your physician or pharmacist about TRUMENBA to schedule an appointment for the first dose. Remember to bring your or your child’s personal immunization records if you have them. You can choose to receive the TRUMENBA brand as your vaccine to help prevent MenB. Feel free to call the vaccination or travel clinic/pharmacy in advance to ask for TRUMENBA by name.
Check out additional resources by clicking here.
